KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2016 - 2018)

Emergent BioSolutions has reported Gains from Sales and Divestitures over the past 8 years, most recently at $427610.0 for Q4 2018.

  • For Q4 2018, Gains from Sales and Divestitures rose 0.89% year-over-year to $427610.0; the TTM value through Dec 2018 reached $427610.0, up 0.89%, while the annual FY2018 figure was $427610.0, 0.89% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2018 was $427610.0 at Emergent BioSolutions, up from $423840.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $427610.0 in Q4 2018 and troughed at $298489.0 in Q1 2014.
  • A 5-year average of $384188.2 and a median of $403992.0 in 2017 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: increased 19.5% in 2015 and later fell 1.0% in 2016.
  • Year by year, Gains from Sales and Divestitures stood at $361010.0 in 2014, then increased by 17.04% to $422515.0 in 2015, then fell by 0.45% to $420599.0 in 2016, then grew by 0.77% to $423840.0 in 2017, then rose by 0.89% to $427610.0 in 2018.
  • Business Quant data shows Gains from Sales and Divestitures for EBS at $427610.0 in Q4 2018, $423840.0 in Q4 2017, and $413752.0 in Q3 2017.